I am finding few bargains even in small caps in this market, mostly raising cash. I do have ATRO, Mexican airports, CVS, UNH, Cognizant as some top positions. In small caps have some ARKR, WSTG, IKNX but quite small positions. The Fed has forced the market up to over valued levels for the most part in my view. I am totally out of Atrion after many years. Nice profits, but now paying large tax bills.
Anyone have an idea justifying the continuing price climb for Atrion shares? Last few earnings reports have not been that great. The EW valves are a threat. I have been selling and only hold a few shares. It has been a great investment for me over many years. But seems quite expensive at present.
Many "roll ups" are great successes: POOL, Danaher, even Berkshire Hathaway, that is not enough to call for shorting...
On the earnings call they were positive on the prospects for the test division. Yes there is uncertainty over the Apple contract, but it is still likely to come again at a lower level. ATRO thinks they have built some unique test capabilities that the industry appreciates and there could be other customers in the future.
Not really they have a price target that represents 35%+ upside. They said that the aerospace business alone is worth more than the current valuation.
Another firm Doughtery also re-stated a BUY rank on ATRO and now have a $50 price target higher than the KeyBanc price target.
Starting to think about what might be the specific candidates here. Of course Lilly is a major company in insulin but I am not sure that would be a target. Perhaps the oncology area where Lilly has products like
Cyramza which is a one hour infusion delivery. Anyone else have ideas?
thanks - sw
SAN DIEGO , Dec. 21, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.(HALO) today announced a global collaboration and license agreement with Eli Lilly and Company(LLY) to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE™ platform.
Under the terms of the agreement, Halozyme will receive an initial $25 million payment, followed by milestone payments of up to $160 million for each of up to five collaboration targets valued at up to $800 million. These payments are subject to Lilly's achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay Halozyme mid-single digit royalties if products under the collaboration are commercialized
When does AMGN partner up?